Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Ozempic® is now available at this reduced price to eligible self-pay LifeMD patientsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -...
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-...
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $14 to $13.
Correction: Lake Street analyst Brooks O'Neil maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $1...
Keybanc analyst Scott Schoenhaus maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the price target from $14 to $12.
